These data show that loss of SETD2 expression in MLL-fusion AML cells interferes with the H3K36me3-H3K79me2-signature on MLL-target genes and impairs chromatin binding of MLL-fusion proteins. This evidence concerns the gene KMT2A and acute myeloid leukemia.